Brief: Alpha Tau Announces Robust Long-Term Safety And Efficacy Data From Multiple Clinical Trials Of Alpha Dart
17/08/2023 22:42
Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES ROBUST LONG-TERM SAFETY AND EFFICACY
DATA
FROM MULTIPLE CLINICAL TRIALS OF ALPHA DART
* ALPHA TAU MEDICAL LTD - NO GRADE 2 OR HIGHER LATE
TOXICITIES
WERE OBSERVED 6 MONTHS AFTER TREATMENT
Source text for Eikon: ID:nGNX3zJK6l
Further company coverage: DRTS.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer